Target intelligence / Profile preview

Urocortin (UCN)

Target
UCN
Molecular classification
Peptide, Neuropeptide, Corticotropin-releasing factor family, Ligand (not receptor/enzyme/transporter), Other
01

Overview

Urocortin is a 40-amino acid peptide protein encoded by the UCN gene in humans and is part of the corticotropin-releasing factor (CRF) family of neuropeptides, which also includes CRF, urocortin II, and urocortin III[1]. It is widely expressed in the central and peripheral nervous systems, as well as in peripheral organs such as the heart[1][10]. Urocortin functions as an endogenous ligand for CRF receptors (particularly CRF type 1 and type 2 receptors) and is a primary ligand for the CRF type 2 receptor due to its higher binding affinity[1][8]. Urocortin regulates the stress response (including the hypothalamic–pituitary–adrenocortical axis), appetite, anxiety, and cardiovascular functions—providing protection against ischemic injury in heart tissue[1][10]. It also modulates cell proliferation through signaling pathways like ERK1/2 (MAPK cascade), in a tissue- and receptor-dependent manner, and may play roles in various diseases such as heart failure, obesity, depression, and inflammatory disorders[3][10].\n—\n**Notes on correctness:**\n- "Urocortin" itself is a neuropeptide ligand, not a classic therapeutic target such as a receptor, enzyme, or transporter.\n- The main therapeutic targets associated with urocortin are its receptors, especially the corticotropin-releasing factor receptor 2 (CRF2 receptor)[1][8].\n- If the intent was to refer to a therapeutic target suitable for drug discovery, "CRF type 2 receptor" (CRF2) would be the appropriate structured entity rather than "urocortin" itself.\n- Therefore, is_target is marked as false and is_incorrect as true for drug targeting purposes.\n\nIf you need structured information on the true drug target ("Corticotropin-releasing factor receptor 2"), please clarify.

Other names
Urocortin (human)UCNUrocortin 1UCN1
02

Biological functions

Regulation of stress responseSignal transductionModulation of appetiteCardioprotection (protects cardiovascular tissue from ischemic injury)Modulation of cell proliferation
03

Disease associations

Cardiovascular diseaseHeart failureGastrointestinal disorders (e.g., irritable bowel syndrome)InflammationObesityDepression
04

Safety considerations

Potential tumor-promoting or tumor-inhibiting effects depending on tissue contextEffects on cardiovascular system when administered systemically

Beyond the preview

Go deeper on Urocortin (UCN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Urocortin (UCN).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call